nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—Epirubicin—uterine cancer	0.116	0.177	CbGbCtD
Dapagliflozin—CYP2A6—Progesterone—uterine cancer	0.104	0.159	CbGbCtD
Dapagliflozin—CYP1A1—Progesterone—uterine cancer	0.0889	0.136	CbGbCtD
Dapagliflozin—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.054	0.0824	CbGbCtD
Dapagliflozin—Vulval abscess—Medroxyprogesterone Acetate—uterine cancer	0.0411	0.184	CcSEcCtD
Dapagliflozin—CYP1A2—Progesterone—uterine cancer	0.0397	0.0606	CbGbCtD
Dapagliflozin—CYP2C9—Progesterone—uterine cancer	0.0358	0.0546	CbGbCtD
Dapagliflozin—ABCB1—Progesterone—uterine cancer	0.0347	0.053	CbGbCtD
Dapagliflozin—CYP2D6—Progesterone—uterine cancer	0.0327	0.0499	CbGbCtD
Dapagliflozin—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0314	0.0479	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—uterine cancer	0.0275	0.042	CbGbCtD
Dapagliflozin—CYP3A4—Progesterone—uterine cancer	0.0208	0.0317	CbGbCtD
Dapagliflozin—Vaginitis bacterial—Medroxyprogesterone Acetate—uterine cancer	0.0198	0.0886	CcSEcCtD
Dapagliflozin—CYP1A2—Etoposide—uterine cancer	0.0178	0.0271	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—uterine cancer	0.0155	0.0237	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—uterine cancer	0.0106	0.0162	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—uterine cancer	0.00999	0.0152	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—uterine cancer	0.00931	0.0142	CbGbCtD
Dapagliflozin—Vulvovaginal pruritus—Progesterone—uterine cancer	0.00719	0.0323	CcSEcCtD
Dapagliflozin—Genital candidiasis—Progesterone—uterine cancer	0.00719	0.0323	CcSEcCtD
Dapagliflozin—Vulvovaginal pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00652	0.0292	CcSEcCtD
Dapagliflozin—SLC5A4—renal system—uterine cancer	0.00646	0.124	CbGeAlD
Dapagliflozin—CYP3A4—Doxorubicin—uterine cancer	0.00635	0.00969	CbGbCtD
Dapagliflozin—Venous thrombosis—Carboplatin—uterine cancer	0.00554	0.0248	CcSEcCtD
Dapagliflozin—SLC5A2—renal system—uterine cancer	0.00489	0.0943	CbGeAlD
Dapagliflozin—Fluid overload—Carboplatin—uterine cancer	0.00481	0.0216	CcSEcCtD
Dapagliflozin—SLC5A1—epithelium—uterine cancer	0.004	0.0771	CbGeAlD
Dapagliflozin—SLC5A1—renal system—uterine cancer	0.00371	0.0715	CbGeAlD
Dapagliflozin—SLC5A1—endometrium—uterine cancer	0.00358	0.0691	CbGeAlD
Dapagliflozin—SLC5A2—vagina—uterine cancer	0.00354	0.0683	CbGeAlD
Dapagliflozin—SLC5A1—mammalian vulva—uterine cancer	0.00347	0.0669	CbGeAlD
Dapagliflozin—Extravasation—Carboplatin—uterine cancer	0.00343	0.0154	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Progesterone—uterine cancer	0.00287	0.0129	CcSEcCtD
Dapagliflozin—Balanitis—Epirubicin—uterine cancer	0.00274	0.0123	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Medroxyprogesterone Acetate—uterine cancer	0.00271	0.0121	CcSEcCtD
Dapagliflozin—SLC5A1—vagina—uterine cancer	0.00269	0.0518	CbGeAlD
Dapagliflozin—Venous thrombosis—Medroxyprogesterone Acetate—uterine cancer	0.00264	0.0118	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Medroxyprogesterone Acetate—uterine cancer	0.0026	0.0117	CcSEcCtD
Dapagliflozin—Balanitis—Doxorubicin—uterine cancer	0.00254	0.0114	CcSEcCtD
Dapagliflozin—Phlebitis—Carboplatin—uterine cancer	0.00252	0.0113	CcSEcCtD
Dapagliflozin—UGT1A9—renal system—uterine cancer	0.00233	0.045	CbGeAlD
Dapagliflozin—UGT2B7—renal system—uterine cancer	0.00188	0.0363	CbGeAlD
Dapagliflozin—Neoplasm malignant—Progesterone—uterine cancer	0.00184	0.00825	CcSEcCtD
Dapagliflozin—Nocturia—Progesterone—uterine cancer	0.00169	0.00759	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Medroxyprogesterone Acetate—uterine cancer	0.00167	0.00748	CcSEcCtD
Dapagliflozin—UGT2B7—female reproductive system—uterine cancer	0.00151	0.029	CbGeAlD
Dapagliflozin—Vaginal infection—Progesterone—uterine cancer	0.00148	0.00665	CcSEcCtD
Dapagliflozin—Neoplasm—Progesterone—uterine cancer	0.00142	0.00637	CcSEcCtD
Dapagliflozin—Vaginal infection—Medroxyprogesterone Acetate—uterine cancer	0.00134	0.00603	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Epirubicin—uterine cancer	0.00132	0.00591	CcSEcCtD
Dapagliflozin—Neoplasm—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00577	CcSEcCtD
Dapagliflozin—Extravasation—Dactinomycin—uterine cancer	0.00127	0.00571	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Doxorubicin—uterine cancer	0.00122	0.00547	CcSEcCtD
Dapagliflozin—Thirst—Progesterone—uterine cancer	0.0012	0.00537	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Medroxyprogesterone Acetate—uterine cancer	0.00119	0.00533	CcSEcCtD
Dapagliflozin—Pain in extremity—Progesterone—uterine cancer	0.00114	0.00511	CcSEcCtD
Dapagliflozin—Thirst—Medroxyprogesterone Acetate—uterine cancer	0.00109	0.00487	CcSEcCtD
Dapagliflozin—Infection—Carboplatin—uterine cancer	0.00106	0.00475	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00475	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00473	CcSEcCtD
Dapagliflozin—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	0.00103	0.00463	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Progesterone—uterine cancer	0.00102	0.00457	CcSEcCtD
Dapagliflozin—CYP2A6—vagina—uterine cancer	0.000976	0.0188	CbGeAlD
Dapagliflozin—Blood creatinine increased—Medroxyprogesterone Acetate—uterine cancer	0.000968	0.00434	CcSEcCtD
Dapagliflozin—Angina pectoris—Progesterone—uterine cancer	0.00096	0.00431	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000943	0.00423	CcSEcCtD
Dapagliflozin—Phlebitis—Dactinomycin—uterine cancer	0.000935	0.0042	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.000924	0.00414	CcSEcCtD
Dapagliflozin—Dysuria—Progesterone—uterine cancer	0.000921	0.00413	CcSEcCtD
Dapagliflozin—Extravasation—Etoposide—uterine cancer	0.000921	0.00413	CcSEcCtD
Dapagliflozin—Pollakiuria—Progesterone—uterine cancer	0.00091	0.00408	CcSEcCtD
Dapagliflozin—Influenza—Medroxyprogesterone Acetate—uterine cancer	0.000893	0.004	CcSEcCtD
Dapagliflozin—Infestation NOS—Progesterone—uterine cancer	0.000878	0.00394	CcSEcCtD
Dapagliflozin—Infestation—Progesterone—uterine cancer	0.000878	0.00394	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Epirubicin—uterine cancer	0.000856	0.00384	CcSEcCtD
Dapagliflozin—Urinary tract infection—Progesterone—uterine cancer	0.000854	0.00383	CcSEcCtD
Dapagliflozin—Body temperature increased—Carboplatin—uterine cancer	0.000843	0.00378	CcSEcCtD
Dapagliflozin—Dysuria—Medroxyprogesterone Acetate—uterine cancer	0.000835	0.00374	CcSEcCtD
Dapagliflozin—Venous thrombosis—Epirubicin—uterine cancer	0.000834	0.00374	CcSEcCtD
Dapagliflozin—Pollakiuria—Medroxyprogesterone Acetate—uterine cancer	0.000825	0.0037	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Epirubicin—uterine cancer	0.000823	0.00369	CcSEcCtD
Dapagliflozin—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.000796	0.00357	CcSEcCtD
Dapagliflozin—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.000796	0.00357	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Doxorubicin—uterine cancer	0.000792	0.00355	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.000785	0.00352	CcSEcCtD
Dapagliflozin—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	0.00078	0.0035	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Progesterone—uterine cancer	0.000779	0.00349	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Progesterone—uterine cancer	0.000775	0.00348	CcSEcCtD
Dapagliflozin—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.000774	0.00347	CcSEcCtD
Dapagliflozin—Urethral disorder—Progesterone—uterine cancer	0.000773	0.00347	CcSEcCtD
Dapagliflozin—Venous thrombosis—Doxorubicin—uterine cancer	0.000772	0.00346	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Doxorubicin—uterine cancer	0.000762	0.00342	CcSEcCtD
Dapagliflozin—CYP1A1—epithelium—uterine cancer	0.000753	0.0145	CbGeAlD
Dapagliflozin—CYP1A1—uterine cervix—uterine cancer	0.000747	0.0144	CbGeAlD
Dapagliflozin—Serum creatinine increased—Epirubicin—uterine cancer	0.000732	0.00328	CcSEcCtD
Dapagliflozin—CYP1A2—renal system—uterine cancer	0.000708	0.0137	CbGeAlD
Dapagliflozin—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.000706	0.00317	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000702	0.00315	CcSEcCtD
Dapagliflozin—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.0007	0.00314	CcSEcCtD
Dapagliflozin—CYP1A1—renal system—uterine cancer	0.000699	0.0135	CbGeAlD
Dapagliflozin—Malnutrition—Progesterone—uterine cancer	0.000686	0.00308	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Doxorubicin—uterine cancer	0.000677	0.00304	CcSEcCtD
Dapagliflozin—Phlebitis—Etoposide—uterine cancer	0.000677	0.00304	CcSEcCtD
Dapagliflozin—Back pain—Progesterone—uterine cancer	0.000664	0.00298	CcSEcCtD
Dapagliflozin—CYP1A1—mammalian vulva—uterine cancer	0.000653	0.0126	CbGeAlD
Dapagliflozin—Lung disorder—Epirubicin—uterine cancer	0.000636	0.00285	CcSEcCtD
Dapagliflozin—Angioedema—Progesterone—uterine cancer	0.000627	0.00281	CcSEcCtD
Dapagliflozin—CYP1A1—uterus—uterine cancer	0.000622	0.012	CbGeAlD
Dapagliflozin—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000622	0.00279	CcSEcCtD
Dapagliflozin—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000602	0.0027	CcSEcCtD
Dapagliflozin—Hypertension—Progesterone—uterine cancer	0.000593	0.00266	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—uterine cancer	0.000589	0.00264	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—uterine cancer	0.000583	0.00262	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00058	0.0026	CcSEcCtD
Dapagliflozin—Discomfort—Progesterone—uterine cancer	0.000577	0.00259	CcSEcCtD
Dapagliflozin—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000568	0.00255	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Progesterone—uterine cancer	0.00056	0.00251	CcSEcCtD
Dapagliflozin—Oedema—Progesterone—uterine cancer	0.00056	0.00251	CcSEcCtD
Dapagliflozin—CYP1A1—female reproductive system—uterine cancer	0.000559	0.0108	CbGeAlD
Dapagliflozin—Infection—Progesterone—uterine cancer	0.000557	0.0025	CcSEcCtD
Dapagliflozin—Skin disorder—Progesterone—uterine cancer	0.000544	0.00244	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Progesterone—uterine cancer	0.000542	0.00243	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—uterine cancer	0.000539	0.00242	CcSEcCtD
Dapagliflozin—CYP2C9—female reproductive system—uterine cancer	0.000538	0.0104	CbGeAlD
Dapagliflozin—Neoplasm malignant—Epirubicin—uterine cancer	0.000527	0.00237	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000526	0.00236	CcSEcCtD
Dapagliflozin—Hypotension—Progesterone—uterine cancer	0.000523	0.00235	CcSEcCtD
Dapagliflozin—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000523	0.00235	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—uterine cancer	0.000516	0.00232	CcSEcCtD
Dapagliflozin—CYP3A4—renal system—uterine cancer	0.000513	0.00988	CbGeAlD
Dapagliflozin—CYP1A1—female gonad—uterine cancer	0.000509	0.00982	CbGeAlD
Dapagliflozin—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000508	0.00228	CcSEcCtD
Dapagliflozin—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000508	0.00228	CcSEcCtD
Dapagliflozin—CYP1A1—vagina—uterine cancer	0.000506	0.00976	CbGeAlD
Dapagliflozin—CYP2D6—renal system—uterine cancer	0.000504	0.00973	CbGeAlD
Dapagliflozin—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000504	0.00226	CcSEcCtD
Dapagliflozin—ABCB1—myometrium—uterine cancer	0.000498	0.00961	CbGeAlD
Dapagliflozin—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000493	0.00221	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000491	0.0022	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—uterine cancer	0.000488	0.00219	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—uterine cancer	0.000485	0.00218	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Progesterone—uterine cancer	0.000484	0.00217	CcSEcCtD
Dapagliflozin—Constipation—Progesterone—uterine cancer	0.000479	0.00215	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—uterine cancer	0.000477	0.00214	CcSEcCtD
Dapagliflozin—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000474	0.00213	CcSEcCtD
Dapagliflozin—Infestation—Etoposide—uterine cancer	0.000449	0.00202	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—uterine cancer	0.000449	0.00202	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—uterine cancer	0.000449	0.00201	CcSEcCtD
Dapagliflozin—Urticaria—Progesterone—uterine cancer	0.000445	0.002	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Etoposide—uterine cancer	0.000443	0.00199	CcSEcCtD
Dapagliflozin—Body temperature increased—Progesterone—uterine cancer	0.000443	0.00199	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—uterine cancer	0.000442	0.00198	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—uterine cancer	0.00044	0.00198	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000438	0.00197	CcSEcCtD
Dapagliflozin—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000434	0.00195	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—uterine cancer	0.000425	0.00191	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—uterine cancer	0.000425	0.00191	CcSEcCtD
Dapagliflozin—Hypersensitivity—Progesterone—uterine cancer	0.000413	0.00185	CcSEcCtD
Dapagliflozin—CYP3A4—female reproductive system—uterine cancer	0.00041	0.00792	CbGeAlD
Dapagliflozin—Discomfort—Dactinomycin—uterine cancer	0.000408	0.00183	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—uterine cancer	0.000407	0.00183	CcSEcCtD
Dapagliflozin—CYP2D6—female reproductive system—uterine cancer	0.000404	0.00779	CbGeAlD
Dapagliflozin—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000403	0.00181	CcSEcCtD
Dapagliflozin—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000401	0.0018	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—uterine cancer	0.000398	0.00179	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—uterine cancer	0.000396	0.00178	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—uterine cancer	0.000395	0.00177	CcSEcCtD
Dapagliflozin—Infection—Dactinomycin—uterine cancer	0.000393	0.00176	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—uterine cancer	0.000393	0.00176	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—uterine cancer	0.000393	0.00176	CcSEcCtD
Dapagliflozin—ABCB1—epithelium—uterine cancer	0.000391	0.00754	CbGeAlD
Dapagliflozin—ABCB1—uterine cervix—uterine cancer	0.000388	0.00748	CbGeAlD
Dapagliflozin—Phlebitis—Epirubicin—uterine cancer	0.000379	0.0017	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—uterine cancer	0.000377	0.00169	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—uterine cancer	0.000376	0.00169	CcSEcCtD
Dapagliflozin—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000374	0.00168	CcSEcCtD
Dapagliflozin—Dizziness—Progesterone—uterine cancer	0.00037	0.00166	CcSEcCtD
Dapagliflozin—ABCB1—decidua—uterine cancer	0.00037	0.00713	CbGeAlD
Dapagliflozin—CYP2D6—female gonad—uterine cancer	0.000368	0.00709	CbGeAlD
Dapagliflozin—ABCB1—renal system—uterine cancer	0.000363	0.007	CbGeAlD
Dapagliflozin—Rash—Progesterone—uterine cancer	0.000353	0.00158	CcSEcCtD
Dapagliflozin—Dermatitis—Progesterone—uterine cancer	0.000353	0.00158	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—uterine cancer	0.000351	0.00157	CcSEcCtD
Dapagliflozin—Headache—Progesterone—uterine cancer	0.000351	0.00157	CcSEcCtD
Dapagliflozin—ABCB1—endometrium—uterine cancer	0.000351	0.00676	CbGeAlD
Dapagliflozin—Diabetes mellitus—Doxorubicin—uterine cancer	0.000348	0.00156	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—uterine cancer	0.00034	0.00152	CcSEcCtD
Dapagliflozin—ABCB1—mammalian vulva—uterine cancer	0.000339	0.00654	CbGeAlD
Dapagliflozin—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000336	0.00151	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—uterine cancer	0.000335	0.0015	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—uterine cancer	0.000334	0.0015	CcSEcCtD
Dapagliflozin—Nausea—Progesterone—uterine cancer	0.000333	0.00149	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—uterine cancer	0.000328	0.00147	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—uterine cancer	0.000327	0.00631	CbGeAlD
Dapagliflozin—Pain in extremity—Epirubicin—uterine cancer	0.000327	0.00147	CcSEcCtD
Dapagliflozin—ABCB1—uterus—uterine cancer	0.000323	0.00623	CbGeAlD
Dapagliflozin—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00032	0.00144	CcSEcCtD
Dapagliflozin—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00032	0.00143	CcSEcCtD
Dapagliflozin—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000318	0.00143	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—uterine cancer	0.000313	0.0014	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—uterine cancer	0.00031	0.00139	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000309	0.00138	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—uterine cancer	0.000306	0.00137	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—uterine cancer	0.000304	0.00136	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—uterine cancer	0.000304	0.00136	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—uterine cancer	0.000303	0.00136	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—uterine cancer	0.000302	0.00136	CcSEcCtD
Dapagliflozin—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000302	0.00135	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—uterine cancer	0.000298	0.00134	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000297	0.00133	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—uterine cancer	0.000295	0.00133	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—uterine cancer	0.000292	0.00131	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—uterine cancer	0.000292	0.00131	CcSEcCtD
Dapagliflozin—ABCB1—female reproductive system—uterine cancer	0.000291	0.0056	CbGeAlD
Dapagliflozin—Anaphylactic shock—Etoposide—uterine cancer	0.000287	0.00129	CcSEcCtD
Dapagliflozin—Infection—Etoposide—uterine cancer	0.000285	0.00128	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—uterine cancer	0.000283	0.00127	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—uterine cancer	0.000282	0.00127	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—uterine cancer	0.000281	0.00126	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—uterine cancer	0.000278	0.00125	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—uterine cancer	0.000277	0.00124	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000276	0.00124	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—uterine cancer	0.000275	0.00123	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—uterine cancer	0.00027	0.00121	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—uterine cancer	0.000268	0.0012	CcSEcCtD
Dapagliflozin—ABCB1—female gonad—uterine cancer	0.000264	0.0051	CbGeAlD
Dapagliflozin—Dysuria—Epirubicin—uterine cancer	0.000264	0.00119	CcSEcCtD
Dapagliflozin—ABCB1—vagina—uterine cancer	0.000263	0.00507	CbGeAlD
Dapagliflozin—Influenza—Doxorubicin—uterine cancer	0.000261	0.00117	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—uterine cancer	0.000261	0.00117	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—uterine cancer	0.000255	0.00114	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—uterine cancer	0.000252	0.00113	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—uterine cancer	0.000252	0.00113	CcSEcCtD
Dapagliflozin—Rash—Dactinomycin—uterine cancer	0.00025	0.00112	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—uterine cancer	0.000248	0.00111	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—uterine cancer	0.000247	0.00111	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—uterine cancer	0.000245	0.0011	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—uterine cancer	0.000245	0.0011	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—uterine cancer	0.000244	0.0011	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—uterine cancer	0.000241	0.00108	CcSEcCtD
Dapagliflozin—Nausea—Dactinomycin—uterine cancer	0.000235	0.00106	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—uterine cancer	0.000233	0.00105	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—uterine cancer	0.000233	0.00105	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—uterine cancer	0.000229	0.00103	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—uterine cancer	0.000228	0.00102	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—uterine cancer	0.000227	0.00102	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—uterine cancer	0.000227	0.00102	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—uterine cancer	0.000223	0.001	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—uterine cancer	0.000222	0.000997	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—uterine cancer	0.000222	0.000994	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—uterine cancer	0.000211	0.000947	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—uterine cancer	0.000207	0.000927	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—uterine cancer	0.000206	0.000922	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—uterine cancer	0.000205	0.00092	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—uterine cancer	0.000197	0.000883	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—uterine cancer	0.00019	0.000854	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—uterine cancer	0.000189	0.00085	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—uterine cancer	0.000182	0.000817	CcSEcCtD
Dapagliflozin—Rash—Etoposide—uterine cancer	0.000181	0.000811	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—uterine cancer	0.000181	0.00081	CcSEcCtD
Dapagliflozin—Headache—Etoposide—uterine cancer	0.00018	0.000805	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—uterine cancer	0.000176	0.00079	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—uterine cancer	0.00017	0.000764	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—uterine cancer	0.00017	0.00328	CbGeAlD
Dapagliflozin—Hypertension—Epirubicin—uterine cancer	0.00017	0.000762	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000166	0.000747	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—uterine cancer	0.000166	0.000743	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—uterine cancer	0.000161	0.000721	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—uterine cancer	0.000161	0.000721	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—uterine cancer	0.00016	0.000716	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—uterine cancer	0.000157	0.000705	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—uterine cancer	0.000156	0.0007	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—uterine cancer	0.000155	0.000697	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000154	0.000691	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—uterine cancer	0.000153	0.000687	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—uterine cancer	0.00015	0.000673	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—uterine cancer	0.000149	0.000667	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—uterine cancer	0.000149	0.000667	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—uterine cancer	0.000148	0.000662	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—uterine cancer	0.000144	0.000648	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—uterine cancer	0.000144	0.000645	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—uterine cancer	0.000139	0.000623	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000139	0.000622	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—uterine cancer	0.000137	0.000616	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000128	0.000576	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—uterine cancer	0.000128	0.000573	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—uterine cancer	0.000127	0.00057	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—uterine cancer	0.000127	0.00057	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—uterine cancer	0.000118	0.000531	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—uterine cancer	0.000118	0.00053	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—uterine cancer	0.000117	0.000527	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—uterine cancer	0.00011	0.000491	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—uterine cancer	0.000106	0.000477	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—uterine cancer	0.000101	0.000454	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—uterine cancer	0.000101	0.000454	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—uterine cancer	0.000101	0.000451	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—uterine cancer	9.83e-05	0.000441	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—uterine cancer	9.54e-05	0.000428	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—uterine cancer	9.37e-05	0.00042	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—uterine cancer	9.36e-05	0.00042	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—uterine cancer	9.31e-05	0.000418	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—uterine cancer	8.83e-05	0.000396	CcSEcCtD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	5.72e-05	0.000824	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PTEN—uterine cancer	5.68e-05	0.000818	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	5.67e-05	0.000816	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	5.65e-05	0.000814	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKR1B1—uterine cancer	5.6e-05	0.000806	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—STAR—uterine cancer	5.6e-05	0.000806	CbGpPWpGaD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	5.54e-05	0.000797	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	5.54e-05	0.000797	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.53e-05	0.000797	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.48e-05	0.000789	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	5.46e-05	0.000786	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	5.45e-05	0.000784	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—EP300—uterine cancer	5.42e-05	0.00078	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—POLD1—uterine cancer	5.41e-05	0.000778	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.39e-05	0.000775	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.39e-05	0.000775	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	5.37e-05	0.000773	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.3e-05	0.000763	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	5.28e-05	0.00076	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	5.2e-05	0.000749	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	5.16e-05	0.000742	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NRAS—uterine cancer	5.07e-05	0.000729	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKR1C1—uterine cancer	5.06e-05	0.000728	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ERBB2—uterine cancer	5.05e-05	0.000727	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ERBB2—uterine cancer	5.05e-05	0.000727	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—MTHFR—uterine cancer	5e-05	0.00072	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	4.87e-05	0.0007	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PTEN—uterine cancer	4.76e-05	0.000685	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	4.72e-05	0.000679	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CDKN1B—uterine cancer	4.67e-05	0.000673	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CDKN1B—uterine cancer	4.67e-05	0.000673	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—VEGFA—uterine cancer	4.65e-05	0.00067	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	4.62e-05	0.000665	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.6e-05	0.000663	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.6e-05	0.000663	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—EP300—uterine cancer	4.54e-05	0.000653	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—RRM2—uterine cancer	4.51e-05	0.000649	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SRD5A2—uterine cancer	4.45e-05	0.00064	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NDUFB11—uterine cancer	4.45e-05	0.00064	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CTNNB1—uterine cancer	4.42e-05	0.000636	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CTNNB1—uterine cancer	4.42e-05	0.000636	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—POLD1—uterine cancer	4.39e-05	0.000632	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—DCN—uterine cancer	4.37e-05	0.00063	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—KRAS—uterine cancer	4.36e-05	0.000628	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.32e-05	0.000622	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKR1B1—uterine cancer	4.32e-05	0.000621	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—STAR—uterine cancer	4.32e-05	0.000621	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PTEN—uterine cancer	4.3e-05	0.00062	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PTEN—uterine cancer	4.3e-05	0.00062	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	4.14e-05	0.000595	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP11A1—uterine cancer	4.12e-05	0.000593	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKR1C1—uterine cancer	4.11e-05	0.000591	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EP300—uterine cancer	4.11e-05	0.000591	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EP300—uterine cancer	4.11e-05	0.000591	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.08e-05	0.000587	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	4.07e-05	0.000586	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	4.06e-05	0.000584	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	4.02e-05	0.000578	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PIK3CA—uterine cancer	4.01e-05	0.000577	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.95e-05	0.000569	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKR1C3—uterine cancer	3.89e-05	0.00056	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRAS—uterine cancer	3.84e-05	0.000553	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRAS—uterine cancer	3.84e-05	0.000553	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HRAS—uterine cancer	3.71e-05	0.000534	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—RRM2—uterine cancer	3.66e-05	0.000527	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTEN—uterine cancer	3.6e-05	0.000519	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTEN—uterine cancer	3.6e-05	0.000519	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—DCN—uterine cancer	3.56e-05	0.000512	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NDUFB11—uterine cancer	3.55e-05	0.000511	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SRD5A2—uterine cancer	3.55e-05	0.000511	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—EP300—uterine cancer	3.44e-05	0.000495	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—EP300—uterine cancer	3.44e-05	0.000495	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	3.43e-05	0.000493	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—POLD1—uterine cancer	3.39e-05	0.000487	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.38e-05	0.000486	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PIK3CA—uterine cancer	3.36e-05	0.000483	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP11A1—uterine cancer	3.35e-05	0.000482	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NDUFB11—uterine cancer	3.35e-05	0.000482	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SRD5A2—uterine cancer	3.35e-05	0.000482	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SRD5A2—uterine cancer	3.32e-05	0.000478	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NDUFB11—uterine cancer	3.32e-05	0.000478	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KRAS—uterine cancer	3.31e-05	0.000476	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KRAS—uterine cancer	3.31e-05	0.000476	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—AKT1—uterine cancer	3.27e-05	0.000471	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.22e-05	0.000464	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKR1B1—uterine cancer	3.22e-05	0.000463	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—STAR—uterine cancer	3.22e-05	0.000463	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	3.18e-05	0.000458	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.18e-05	0.000457	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKR1C1—uterine cancer	3.17e-05	0.000456	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKR1C3—uterine cancer	3.16e-05	0.000455	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.04e-05	0.000438	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PIK3CA—uterine cancer	3.04e-05	0.000437	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PIK3CA—uterine cancer	3.04e-05	0.000437	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—STK11—uterine cancer	3.03e-05	0.000437	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP19A1—uterine cancer	3.03e-05	0.000437	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.98e-05	0.000429	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NDUFB11—uterine cancer	2.84e-05	0.000408	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SRD5A2—uterine cancer	2.84e-05	0.000408	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—RRM2—uterine cancer	2.82e-05	0.000406	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—uterine cancer	2.81e-05	0.000404	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—uterine cancer	2.81e-05	0.000404	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTEN—uterine cancer	2.78e-05	0.000401	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.76e-05	0.000397	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.75e-05	0.000396	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AKT1—uterine cancer	2.74e-05	0.000395	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—DCN—uterine cancer	2.74e-05	0.000395	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—EP300—uterine cancer	2.65e-05	0.000382	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.61e-05	0.000375	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.6e-05	0.000374	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP11A1—uterine cancer	2.58e-05	0.000372	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—STAR—uterine cancer	2.57e-05	0.00037	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKR1B1—uterine cancer	2.57e-05	0.00037	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CA—uterine cancer	2.54e-05	0.000366	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CA—uterine cancer	2.54e-05	0.000366	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.54e-05	0.000366	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—POLD1—uterine cancer	2.52e-05	0.000363	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—AKT1—uterine cancer	2.48e-05	0.000357	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—AKT1—uterine cancer	2.48e-05	0.000357	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP19A1—uterine cancer	2.46e-05	0.000355	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—STK11—uterine cancer	2.46e-05	0.000355	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKR1C3—uterine cancer	2.44e-05	0.000351	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.42e-05	0.000349	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—STAR—uterine cancer	2.42e-05	0.000348	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKR1B1—uterine cancer	2.42e-05	0.000348	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—STAR—uterine cancer	2.4e-05	0.000345	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.4e-05	0.000345	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.37e-05	0.000341	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKR1C1—uterine cancer	2.36e-05	0.00034	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.31e-05	0.000333	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.3e-05	0.00033	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—MTHFR—uterine cancer	2.28e-05	0.000328	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.21e-05	0.000318	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.19e-05	0.000315	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.19e-05	0.000315	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—RRM2—uterine cancer	2.1e-05	0.000303	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—uterine cancer	2.08e-05	0.000299	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—uterine cancer	2.08e-05	0.000299	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKR1B1—uterine cancer	2.05e-05	0.000295	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—STAR—uterine cancer	2.05e-05	0.000295	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—DCN—uterine cancer	2.04e-05	0.000294	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.03e-05	0.000292	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—POLD1—uterine cancer	2.02e-05	0.00029	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—uterine cancer	1.96e-05	0.000283	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.95e-05	0.000281	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP11A1—uterine cancer	1.92e-05	0.000277	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP19A1—uterine cancer	1.9e-05	0.000273	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—STK11—uterine cancer	1.9e-05	0.000273	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—POLD1—uterine cancer	1.9e-05	0.000273	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKR1C1—uterine cancer	1.88e-05	0.000271	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—POLD1—uterine cancer	1.88e-05	0.000271	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—MTHFR—uterine cancer	1.85e-05	0.000267	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.82e-05	0.000262	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.79e-05	0.000258	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.78e-05	0.000256	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.76e-05	0.000253	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.73e-05	0.00025	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RRM2—uterine cancer	1.68e-05	0.000242	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.63e-05	0.000235	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—DCN—uterine cancer	1.63e-05	0.000235	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—POLD1—uterine cancer	1.61e-05	0.000232	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—uterine cancer	1.6e-05	0.000231	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RRM2—uterine cancer	1.58e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—STAR—uterine cancer	1.58e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.58e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RRM2—uterine cancer	1.57e-05	0.000226	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—DCN—uterine cancer	1.54e-05	0.000221	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP11A1—uterine cancer	1.54e-05	0.000221	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—DCN—uterine cancer	1.52e-05	0.000219	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.5e-05	0.000217	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.46e-05	0.000211	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKR1C3—uterine cancer	1.45e-05	0.000209	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.45e-05	0.000208	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.44e-05	0.000207	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MTHFR—uterine cancer	1.43e-05	0.000205	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—STK11—uterine cancer	1.42e-05	0.000204	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP19A1—uterine cancer	1.42e-05	0.000204	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.37e-05	0.000197	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.36e-05	0.000195	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RRM2—uterine cancer	1.34e-05	0.000193	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.33e-05	0.000191	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—DCN—uterine cancer	1.3e-05	0.000187	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—uterine cancer	1.27e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.27e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—POLD1—uterine cancer	1.24e-05	0.000179	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.23e-05	0.000177	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—uterine cancer	1.21e-05	0.000174	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.16e-05	0.000167	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.16e-05	0.000167	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—STK11—uterine cancer	1.13e-05	0.000163	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP19A1—uterine cancer	1.13e-05	0.000163	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.07e-05	0.000153	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—STK11—uterine cancer	1.07e-05	0.000153	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—uterine cancer	1.06e-05	0.000153	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.06e-05	0.000152	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—STK11—uterine cancer	1.06e-05	0.000152	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RRM2—uterine cancer	1.04e-05	0.000149	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—uterine cancer	1.03e-05	0.000148	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—DCN—uterine cancer	1e-05	0.000145	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.91e-06	0.000143	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—uterine cancer	9.82e-06	0.000141	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP11A1—uterine cancer	9.47e-06	0.000136	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.45e-06	0.000136	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.37e-06	0.000135	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—STK11—uterine cancer	9.02e-06	0.00013	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP19A1—uterine cancer	9.02e-06	0.00013	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—uterine cancer	8.94e-06	0.000129	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKR1C3—uterine cancer	8.94e-06	0.000129	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—uterine cancer	8.49e-06	0.000122	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.47e-06	0.000122	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.08e-06	0.000116	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—uterine cancer	8e-06	0.000115	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—uterine cancer	7.94e-06	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—uterine cancer	7.94e-06	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—uterine cancer	7.57e-06	0.000109	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—uterine cancer	7.31e-06	0.000105	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—uterine cancer	7.27e-06	0.000105	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.99e-06	0.000101	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—STK11—uterine cancer	6.96e-06	0.0001	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.96e-06	0.0001	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—uterine cancer	6.78e-06	9.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.98e-06	8.6e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—uterine cancer	5.94e-06	8.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—uterine cancer	5.92e-06	8.52e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—uterine cancer	5.64e-06	8.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—uterine cancer	5.6e-06	8.06e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—uterine cancer	5.23e-06	7.53e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—uterine cancer	4.73e-06	6.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—uterine cancer	4.58e-06	6.59e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—uterine cancer	4.51e-06	6.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—uterine cancer	4.45e-06	6.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—uterine cancer	4.41e-06	6.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—uterine cancer	4.25e-06	6.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—uterine cancer	4.21e-06	6.06e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—uterine cancer	4.17e-06	6.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—uterine cancer	3.77e-06	5.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—uterine cancer	3.6e-06	5.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—uterine cancer	3.41e-06	4.91e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—uterine cancer	3.33e-06	4.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.14e-06	4.52e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.11e-06	4.48e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—uterine cancer	2.91e-06	4.19e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—uterine cancer	2.78e-06	4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—uterine cancer	2.72e-06	3.92e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.66e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—uterine cancer	2.57e-06	3.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—uterine cancer	2.54e-06	3.66e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—uterine cancer	2.17e-06	3.13e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.05e-06	2.96e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—uterine cancer	1.68e-06	2.42e-05	CbGpPWpGaD
